FY2024 EPS Estimates for MDxHealth Boosted by William Blair

MDxHealth SA (NASDAQ:MDXH) – Equities researchers at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of MDxHealth in a research note issued to investors on Monday, November 11th. William Blair analyst A. Brackmann now forecasts that the company will post earnings of ($1.08) per share for the year, up from their previous forecast of ($1.11). The consensus estimate for MDxHealth’s current full-year earnings is ($1.16) per share. William Blair also issued estimates for MDxHealth’s Q4 2024 earnings at ($0.16) EPS, Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.53) EPS.

Several other research analysts have also commented on the company. Piper Sandler lowered their price target on MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th. Lake Street Capital started coverage on MDxHealth in a report on Thursday, October 31st. They issued a “buy” rating and a $7.00 target price on the stock.

MDxHealth Stock Down 2.8 %

NASDAQ MDXH opened at $1.75 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. The stock has a fifty day simple moving average of $2.19 and a 200-day simple moving average of $2.57. MDxHealth has a twelve month low of $1.62 and a twelve month high of $4.64.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Wednesday, August 21st. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.05). The firm had revenue of $22.16 million during the quarter, compared to analyst estimates of $20.66 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%.

Hedge Funds Weigh In On MDxHealth

A number of hedge funds have recently modified their holdings of MDXH. OneDigital Investment Advisors LLC raised its stake in shares of MDxHealth by 15.3% during the third quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock worth $120,000 after purchasing an additional 7,656 shares during the last quarter. MVM Partners LLC grew its holdings in MDxHealth by 3.3% in the third quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock valued at $9,706,000 after purchasing an additional 150,000 shares during the last quarter. Finally, Perkins Capital Management Inc. increased its position in shares of MDxHealth by 70.7% in the third quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock valued at $1,555,000 after buying an additional 309,500 shares in the last quarter.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.